Positive News SentimentPositive NewsNASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Price, News & Analysis $6.89 -0.30 (-4.17%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.84 -0.05 (-0.71%) As of 05:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Treace Medical Concepts Stock (NASDAQ:TMCI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TMCI alerts:Sign Up Key Stats Today's Range$6.88▼$7.3050-Day Range$5.34▼$7.7052-Week Range$4.54▼$10.79Volume697,518 shsAverage Volume313,624 shsMarket Capitalization$435.24 millionP/E RatioN/ADividend YieldN/APrice Target$9.83Consensus RatingHold Company Overview Treace Medical Concepts, Inc. is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates. The Lapiplasty System has received clearance from the U.S. Food and Drug Administration and is supported by clinical evidence demonstrating its effectiveness for patients with moderate to severe bunion deformities. Treace works closely with a network of foot and ankle surgeons, offering hands-on training programs and educational resources to facilitate proper adoption of its technology in hospital and ambulatory surgery center settings. In addition to bunion correction, the company continues to explore adjacent applications in foot and ankle reconstruction. Founded in 2017 and headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts initially built its commercial presence in North America and is evaluating opportunities for international expansion. The company’s management team brings together experienced medical device executives, orthopedic surgeons, and industry veterans committed to advancing the standard of care in foot and ankle surgery. Treace continues to invest in research and development as it seeks to broaden its product portfolio and drive long-term growth in the orthopedic market.AI Generated. May Contain Errors. Read More Treace Medical Concepts Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreTMCI MarketRank™: Treace Medical Concepts scored higher than 53% of companies evaluated by MarketBeat, and ranked 487th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingTreace Medical Concepts has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialTreace Medical Concepts has a consensus price target of $9.83, representing about 42.7% upside from its current price of $6.89.Amount of Analyst CoverageTreace Medical Concepts has only been the subject of 3 research reports in the past 90 days.Read more about Treace Medical Concepts' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.92) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Treace Medical Concepts' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.03% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 4.26%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.03% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 4.26%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment1.61 News SentimentTreace Medical Concepts has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Treace Medical Concepts this week, compared to 9 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.Percentage Held by Insiders27.72% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Treace Medical Concepts' insider trading history. Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TMCI Stock News HeadlinesTreace Medical Concepts Insider Ups Holding During YearSeptember 21 at 4:15 PM | finance.yahoo.comTreace Medical Concepts, Inc.: Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual ...September 10, 2025 | finanznachrichten.deBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. | Banyan Hill Publishing (Ad)Treace Medical to highlight product innovations, data for ALIGN3D, MTA3DSeptember 10, 2025 | msn.comTreace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual MeetingSeptember 10, 2025 | globenewswire.comTreace Medical Concepts, Inc. (TMCI) Investor Day 2025 Call TranscriptSeptember 3, 2025 | seekingalpha.comTreace Medical Concepts: Positive Q2 Earnings Call HighlightsAugust 12, 2025 | tipranks.comAnalysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest ReportAugust 12, 2025 | finance.yahoo.comSee More Headlines TMCI Stock Analysis - Frequently Asked Questions How have TMCI shares performed this year? Treace Medical Concepts' stock was trading at $7.44 on January 1st, 2025. Since then, TMCI shares have decreased by 7.4% and is now trading at $6.89. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. The firm earned $47.39 million during the quarter, compared to analysts' expectations of $47.08 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 46.76% and a negative net margin of 23.01%. Read the conference call transcript. When did Treace Medical Concepts IPO? Treace Medical Concepts (TMCI) raised $150 million in an initial public offering on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Top institutional investors of Treace Medical Concepts include Armistice Capital LLC (9.91%), William Blair Investment Management LLC (4.93%), Gagnon Securities LLC (3.58%) and JPMorgan Chase & Co. (2.81%). Insiders that own company stock include John T Treace, James T Treace, Thomas E Timbie, Richard W Mott, Sean F Scanlan, Deepti Jain, Daniel E Owens, Mark Hair, Scot Michael Elder, Aaron Berutti and F Barry Bays. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Treace Medical Concepts own? Based on aggregate information from My MarketBeat watchlists, some other companies that Treace Medical Concepts investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/07/2025Today9/22/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMCI CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Price Target for Treace Medical Concepts$9.83 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+42.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.74 million Net Margins-23.01% Pretax Margin-23.01% Return on Equity-46.76% Return on Assets-23.35% Debt Debt-to-Equity Ratio0.55 Current Ratio3.52 Quick Ratio2.51 Sales & Book Value Annual Sales$209.36 million Price / Sales2.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.81 per share Price / Book3.81Miscellaneous Outstanding Shares63,170,000Free Float45,661,000Market Cap$435.24 million OptionableOptionable Beta0.71 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TMCI) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Treace Medical Concepts With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.